{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:16:20Z","timestamp":1790424980649,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH\/NINDS","award":["R01 NS097147"],"award-info":[{"award-number":["R01 NS097147"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T10:22:28Z","timestamp":1531218148000},"page":"5046-5057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection"],"prefix":"10.1016","volume":"36","author":[{"given":"Ria","family":"Mulherkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykan","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashida","family":"Ginwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramila","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishomwa C.","family":"Ndhlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar K.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.07.002_b0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0010","doi-asserted-by":"crossref","first-page":"P85","DOI":"10.1186\/1742-4690-12-S1-P85","article-title":"Molecular epidemiology of HTLV-1 in Argentina","volume":"12","author":"Pineda","year":"2015","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0015","doi-asserted-by":"crossref","first-page":"e2643","DOI":"10.1371\/journal.pntd.0002643","article-title":"Clinical associations of Human T-Lymphotropic Virus type 1 infection in an indigenous Australian population","volume":"8","author":"Einsiedel","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.002_b0020","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S1473-3099(16)30252-3","article-title":"Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis","volume":"16","author":"Satake","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.002_b0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/jmv.24745","article-title":"High risk of heterosexual transmission of human T-cell lymphotropic virus type 1 infection in Brazil","volume":"89","author":"Paiva","year":"2017","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.002_b0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CMR.00063-09","article-title":"Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases","volume":"23","author":"Gon\u00e7alves","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.virol.2012.09.028","article-title":"HTLV-1: persistence and pathogenesis","volume":"435","author":"Cook","year":"2013","journal-title":"Virology"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.07.002_b0040","doi-asserted-by":"crossref","first-page":"O19","DOI":"10.1186\/1742-4690-12-S1-O19","article-title":"The clinical spectrum of HTLV-1 infection","volume":"12","author":"Tanajura","year":"2015","journal-title":"Retrovirology."},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.002_b0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0036-46652012000300002","article-title":"HTLV-1\/2 seroprevalence and coinfection rate in Brazilian first-time blood donors: an 11-year follow-up","volume":"54","author":"Pinto","year":"2012","journal-title":"Revista do Instituto de Medicina Tropical de S\u00e3o Paulo."},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.002_b0050","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/jcp.2007.052456","article-title":"Adult T-cell leukaemia\/lymphoma","volume":"60","author":"Matutes","year":"2007","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.002_b0055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ncl.2008.03.008","article-title":"Treatment of HTLV-I-Associated myelopathy\/tropical spastic paraparesis: toward rational targeted therapy","volume":"26","author":"Oh","year":"2008","journal-title":"Neurol Clin"},{"key":"10.1016\/j.vaccine.2018.07.002_b0060","doi-asserted-by":"crossref","unstructured":"Saito M, Jain P, Tsukasaki K, Bangham CRM. HTLV-1 infection and its associated diseases. Leukemia Res Treat 2012;2012:1-.","DOI":"10.1155\/2012\/123637"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.002_b0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/rmv.1745","article-title":"Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1: Mechanism of HTLV-1 associated diseases","volume":"23","author":"Satou","year":"2013","journal-title":"Rev Med Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.07.002_b0070","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2015-06-652040","article-title":"A vaccine against HTLV-1 HBZ makes sense","volume":"126","author":"Mahieux","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/1471-2334-14-453","article-title":"Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers","volume":"14","author":"Coutinho","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2018.07.002_b0080","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.vaccine.2014.03.087","article-title":"In vivo immunogenicity of Tax(11\u201319) epitope in HLA-A2\/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine","volume":"32","author":"Sagar","year":"2014","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2018.07.002_b0085","doi-asserted-by":"crossref","first-page":"34581","DOI":"10.1074\/jbc.M707317200","article-title":"Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein","volume":"282","author":"Jain","year":"2007","journal-title":"J Biol Chem"},{"issue":"32","key":"10.1016\/j.vaccine.2018.07.002_b0090","doi-asserted-by":"crossref","first-page":"22284","DOI":"10.1074\/jbc.M114.549659","article-title":"Human T-lymphotropic virus type 1-infected cells secrete exosomes that contain Tax protein","volume":"289","author":"Jaworski","year":"2014","journal-title":"J Biol Chem"},{"issue":"s2","key":"10.1016\/j.vaccine.2018.07.002_b0095","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1086\/344269","article-title":"Immunopathogenesis of human t cell lymphotropic virus type i-associated neurologic disease","volume":"186","author":"Jacobson","year":"2002","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.002_b0100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10875-013-9918-x","article-title":"Lack of recall response to tax in ATL and HAM\/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1","volume":"33","author":"Manuel","year":"2013","journal-title":"J Clin Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.002_b0105","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.humimm.2011.07.308","article-title":"Programmed death-1 (PD-1)\/PD-1 ligand pathway\u2013mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy\/tropical spastic paraparesis and carriers with autoimmune disorders","volume":"72","author":"Kozako","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2018.07.002_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/860562","article-title":"MHC class I presented T cell epitopes as potential antigens for therapeutic vaccine against HBV chronic infection","volume":"2014","author":"Comber","year":"2014","journal-title":"Hepatitis Res Treat"},{"key":"10.1016\/j.vaccine.2018.07.002_b0115","series-title":"MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines","first-page":"77","author":"Comber","year":"2014"},{"key":"10.1016\/j.vaccine.2018.07.002_b0120","unstructured":"Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, et al. MHC Class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response: e48484. PLoS One U6 - ctx_ver=Z3988-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummonserialssolutionscom&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rftgenre=article&rftatitle=MHC+Class+I-Presented+T+Cell+Epitopes+Identified+by+Immunoproteomics+Analysis+Are+Targets+for+a+Cross+Reactive+Influenza-Specific+T+Cell+Response&rftjtitle=PLoS+One&rftau=James+S+Testa&rftau=Vivekananda+Shetty&rftau=Julie+Hafner&rftau=Zacharie+Nickens&rftdate=2012-11-01&rftpub=Public+Library+of+Science&rfteissn=1932-6203&rftvolume=7&rftissue=11&rft_id=info:doi\/101371%2Fjournalpone0048484&rftexternalDocID=2944394431&paramdict=en-US U7 - Journal Article. 2012;7(11)"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.002_b0125","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jprot.2011.02.020","article-title":"MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response","volume":"74","author":"Shetty","year":"2011","journal-title":"J Proteom"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2018.07.002_b0130","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1099\/vir.0.80766-0","article-title":"A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load","volume":"86","author":"Asquith","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.07.002_b0135","doi-asserted-by":"crossref","unstructured":"Mittendorf E, Hueman M, Storrer C, Shriver C, Ponnaiah S, Peoples G. Evaluation of the Cd107a cytotoxicity assay for the detection of cytolytic CD8 cells recognizing Her2\/neu vaccine peptides. J Surg Res 2004;121(2):327-.","DOI":"10.1016\/j.jss.2004.07.194"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.002_b0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/v8010005","article-title":"HTLV-1, Immune Response and Autoimmunity","volume":"8","author":"Quaresma","year":"2016","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.002_b0150","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.virol.2003.07.001","article-title":"Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation","volume":"315","author":"van der Most","year":"2003","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.002_b0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.193.2.181","article-title":"Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection","volume":"193","author":"Goulder","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.07.002_b0165","doi-asserted-by":"crossref","unstructured":"Jellison ER, Turner MJ, Blair DA, Lingenheld EG, Zu L, Puddington L, et al. Distinct mechanisms mediate na\u00efve and memory CD8 T-cell tolerance. Proc Natl Acad Sci USA 2012;109(52):21438-21443.","DOI":"10.1073\/pnas.1217409110"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.002_b0170","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.4049\/jimmunol.1101579","article-title":"Badovinac VP. Population dynamics of naive and memory CD8 T cell responses after antigen stimulations in vivo","volume":"188","author":"Martin","year":"2012","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.002_b0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.20131271","article-title":"Memory CD8+ T cells exhibit increased antigen threshold requirements for recall proliferation","volume":"211","author":"Mehlhop-Williams","year":"2014","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.002_b0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2222\/jsv.50.37","article-title":"Genetic diversity of HLA in HTLV-I infection","volume":"50","author":"Sonoda","year":"2000","journal-title":"Uirusu"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.002_b0185","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/prot.21117","article-title":"An FFT-based protein docking program with pairwise potentials","volume":"65","author":"Kozakov","year":"2006","journal-title":"Proteins: Struct, Funct, Bioinf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:52Z","timestamp":1759400812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18309320"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}